6th September 2019 – Global Insomnia
Therapeutics Market is anticipated to reach USD 3.45 billion by 2025.
Insomnia Therapy implies different patterns of treatment to address trouble
with respect to initiation as well as maintenance of sleep. These sleep
disorders are termed as “Insomnia”. Insomnia results in non-productive work
hours. If left untreated, this condition may lead to a nervous breakdown and/or
depression in the patient. The symptoms include daytime sleepiness, low
stamina, irritability, and depression. It is a dominant disorder that affects
millions of people, globally.
The factors that propel the growth of
the Insomnia Therapeutics Market include growing medical strategies, increase
in the number of mental disorders, rising aged population, and increasing
stress level, introduction of technically advanced medical devices, and
increasing awareness among people. On the other hand, there are factors that
may hamper the growth of the market such as Insomnia therapeutic drugs may lead
to several allergies, and the other side effects. Insomnia Therapeutics Market
is anticipated to grow at a significant CAGR of 5.3% in the upcoming period as
the scope, product types, and its applications are increasing across the globe.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/insomnia-therapeutics-market/request-sample
Insomnia Therapeutics Market may be
explored by therapy type, sale channel, and geography. The market may be
explored by Therapy type as Nonbenzodiazepines, Benzodiazepines,
Antidepressants, Melatonin Antagonists, Orexin Antagonists, and Others, and
Medical Devices. The “Drugs” segment dominated the Insomnia Therapeutics Market
in 2016 and is anticipated to maintain its dominance by 2025 owing to higher
acceptance of drugs as compared to devices, and due to easy availability and
quick results.
The market may be explored by sale
channel as Prescription, and Over-the-Counter (OTC). The “Over-the-Counter(OTC)”
segment dominated the Insomnia Therapeutics Market in 2016 and is anticipated
to maintain its dominance by 2025 and accounted for approximately 79.2% of the
total market revenue.
North America accounted for the major
share of the Insomnia Therapeutics Market Size in 2016 and will continue to
lead in the forecast period. The factors that could be attributed to the growth
include growing aged population, high adoption of therapeutics for treatment,
and increase in awareness about diseases. North America is followed by
Asia-Pacific region. Some of the key players that fuel the growth of the
Insomnia Therapeutics Market comprise Sanofi, Pfizer, Inc., ECR
Pharmaceuticals, Merck & Co. Inc., Pernix Therapeutics, Purdue
Pharmaceuticals L.P., Eisai, Co. Ltd., Vanda Pharmaceuticals, Takeda
Pharmaceutical Company Ltd., and Meda Consumer Healthcare Inc. The leading
companies are taking up partnerships, mergers and acquisitions, and joint
ventures in order to boost the inorganic growth of the industry.
For More Details, Visit @ http://www.millioninsights.com
No comments:
Post a Comment